Four important new recruitments for continuous progressProlight Diagnostics is pleased to announce successful recruitments to four key positions in its fully owned UK subsidiary Psyros Diagnostics. As previously announced, the company was acquired in the beginning of the year and the work on the continuous development of Psyros' unique digital immunoassay platform is progressing according to plan. Three of the new recruits are already in full employment: Senior Scientist Marc Swayne, Systems Engineer Sam Fincham and Mechanical Engineer Daniel Hollands. "We are delighted to announce our new recruits, who are critical to our continued development work. We are also pleased to announce that we have hired a Head of Quality and Regulatory Affairs, Andrew Goodenough, who will lead the important implementation of our safety and quality management system as well as the regulatory work", says Tobias Volker, Acting Managing Director of Psyros Diagnostics.
"With these important additions to our team, we will be able to continue to develop instruments and cartridges with high quality, fully in line with our ambitious objectives", comments Ulf Bladin, CEO of Prolight Diagnostics. For further information, please contact:
Prolight Diagnostics AB (publ)
E-mail: [email protected]
Ph.: +46 73 582 39 87
Website: http://www.prolightdiagnostics.se/en/
The following documents can be retrieved from beQuoted
Prolight Diagnostics Pressrelease 2022-06-30.pdf Prolight Diagnostics, develops together with fully owned subsidiary Psyros Diagnostics and technology partners, innovative, flexible, patient-oriented testing systems, Point Of Care Testing (POCT) based on patented technology. POC testing is performed outside the traditional hospital laboratory with small mobile instruments in places such as health centres, nursing homes, emergency departments and intensive care units, enabling testing close to the patient and with rapid test results. This technology will allow healthcare providers to distinguish at an early stage those patients who need urgent care from those who do not, for example, have a heart attack. Prolight Diagnostics has been developing "micro ELISA" for point of care testing for a decade. The sales value in the POCT area amounted to USD 29.1 billion in 2020 and is growing strongly.
The company's shares are traded under the short name PRLD on the NGM Nordic SME marketplace. G&W Fondkommission is the mentor, phone: 08-503 000 50.
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 